| Jennifer J. Dotterweich, Od, Pllc | |
|
243 E Main St, Avon, NY 14414-1421 | |
| (585) 519-4208 | |
| Not Available |
| Full Name | Jennifer J. Dotterweich, Od, Pllc |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 243 E Main St, Avon, New York |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659569606 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | VUT006150-1 (New York) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Jennifer J. Dotterweich, Od, Pllc 243 E Main St, Avon, NY 14414-1421 Ph: (585) 519-4208 | Jennifer J. Dotterweich, Od, Pllc 243 E Main St, Avon, NY 14414-1421 Ph: (585) 519-4208 |
News Archive
New Mexico's healthcare disparity might just get worse - a hard concept to fathom given that the State has some of the most underserved areas in the country. The New Mexico Behavioral Health Collaborative, started by Governor Bill Richardson in 2004 to address "the way in which the [behavioral health] services are paid for and delivered," is coming under heavy fire from doctors around the State. The Collaborative has statutory authority and has been given broad powers that often surpass even department heads.
Sinclair IS Pharma Plc, the international specialty pharmaceutical company, and Invida Holdings Private Limited, a leader in the commercialisation of specialty biopharmaceutical and healthcare products throughout Asia Pacific, announce that their partnership has already led to the launch of two Sinclair IS dermatology products in seven Asia-Pacific markets.
Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a Mayo Clinic researcher who co-led PERSIST-1, the worldwide phase III clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent.
An implantable brain device meant to help Parkinson's disease patients better control their movements, has been found to have some worrying side-effects.
› Verified 9 days ago
Jennifer J Dotterweich, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 243 E Main St, Avon, NY 14414 Phone: 585-519-4208 Fax: 585-438-4148 | |
Livingston Eye Care Optometrist Medicare: Medicare Enrolled Practice Location: 243 E Main St, Avon, NY 14414 Phone: 585-226-3400 Fax: 585-438-4148 | |
Christine Dayton White, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 128 Genesee St, Avon, NY 14414 Phone: 585-226-3400 Fax: 585-226-3400 |